Balyasny Asset Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Balyasny Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.29M	Buy	+126,600	New	+$4.22M	0.01%	1451
2026 Q1	–	Sell	-192,600	Closed	-$6.01M	–	3512
2025 Q4	$6.01M	Buy	192,600 +135,400	+237%	+$3.34M	0.01%	1297
2025 Q3	$1.16M	Buy	+57,200	New	+$1M	﹤0.01%	2056
2025 Q1	–	Sell	-53,300	Closed	-$1.17M	–	3275
2024 Q4	$1.17M	Sell	53,300 -42,500	-44%	-$773K	﹤0.01%	1879
2024 Q3	$1.73M	Buy	+95,800	New	+$1.68M	﹤0.01%	1732
2018 Q3	–	Sell	-695,000	Closed	-$16.9M	–	2031
2018 Q2	$16.9M	Buy	+695,000	New	+$14.2M	0.08%	351
2018 Q1	–	Sell	-700,000	Closed	-$13.3M	–	2301
2017 Q4	$13.3M	Buy	700,000 +500,000	+250%	+$7.52M	0.04%	548
2017 Q3	$3.52M	Buy	+200,000	New	+$4.5M	0.01%	821
2016 Q2	–	Sell	-340,000	Closed	-$18.2M	–	1441
2016 Q1	$18.2M	Buy	+340,000	New	+$19.9M	0.11%	267

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Balyasny Asset Management's TEVA Position: Q2 2025 in Review

Balyasny Asset Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2025, closing a stake of 28,613 shares — an estimated $440K sold.

Balyasny Asset Management first reported a position in TEVA in Q2 2013 and held it in 31 quarters. The position peaked at $223M in Q4 2015. 541 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

Balyasny Asset Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2025 after selling out during the quarter.
Balyasny Asset Management sold 28,613 Teva Pharmaceutical Industries Limited shares in Q2 2025, an estimated $440K.
Balyasny Asset Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 31 quarters.
Balyasny Asset Management's Teva Pharmaceutical Industries Limited position peaked at $223M in Q4 2015.
541 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.